Dupixent Asthma denied due to quantity / dose limits by Aetna?

Aetna's specific coverage criteria for dupixent asthma are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Limits the Quantity of Dupixent for Asthma — and How to Appeal

Aetna quantity-limit denials for dupilumab (Dupixent) in asthma typically arise when the amount prescribed — the number of syringes or pens per dispensing period — exceeds the quantity the plan's policy designates as a "standard" supply. This can happen if your physician prescribed a loading dose sequence or a dosing interval that differs from the plan's reference dosing assumption, or if a refill was requested before the plan's minimum days-supply interval.

### Why This Denial Is Appealable

Quantity limits must be applied consistently with the FDA-approved prescribing information. If your physician is prescribing within the FDA-approved dosing framework and the quantity is medically necessary for your condition, Aetna must evaluate that on clinical grounds rather than applying a blanket limit. Under ERISA §503 and ACA §2719, you are entitled to a full-and-fair internal appeal followed by independent external review. External reviewers have authority to override a quantity limit when the record demonstrates the prescribed quantity is consistent with the FDA label and medically appropriate.

### Your Appeal Timeline

• Internal appeal: File within the deadline on your denial notice (commonly 180 days for ERISA plans). Decisions within 30–60 days; expedited within 72 hours for urgent situations.
• External review: After internal denial, approximately four months to request independent external review.

### Documentation to Gather

1. FDA-approved prescribing information for dupilumab — attach the current label from the FDA website. Identify the approved dosing regimen for your indication, including any initial dose or loading sequence, so the reviewer can confirm the quantity ordered is within the approved range. 2. Prescriber's dosing rationale — a letter from your physician explaining the specific quantity ordered, why it corresponds to the FDA-approved regimen, and why it is medically necessary for your case. 3. Diagnosis and severity documentation — chart notes confirming asthma diagnosis, severity, and phenotype consistent with the FDA-approved indication. 4. Refill timing documentation — if the denial was based on early refill, include documentation of any dose wasted, lost, or consumed faster than expected due to a clinical event, and your physician's explanation. 5. Clinical progress notes — evidence of treatment response that supports continued use at the prescribed quantity.

### Criteria-Mapping Structure

Obtain Aetna's quantity-limit policy for dupilumab in asthma. Map each component to your record:

| Quantity-Limit Criterion | Your Evidence | |---|---| | Quantity consistent with FDA dosing | [FDA label dosing section, prescriber letter] | | Medical necessity for quantity requested | [Physician letter explaining clinical rationale] | | Diagnosis consistent with approved indication | [Chart note, PFT results] |

Review the FDA-approved prescribing information carefully before filing so your appeal letter speaks directly to the approved dosing language.